Skip to main content
SpringerLink
Log in

Antihypertonika

  • Chapter
Arzneiverordnungs- Report 2014

  • 1554 Accesses

Zusammenfassung

In diesem Kapitel zu speziellen Antihypertonika werden neben den Empfehlungen zur antihypertensiven Therapie Alpharezeptorenblocker und zentral wirkende Antisympathotonika sowie Kombinationspräparate von Betarezeptorenblockern und Calciumantagonisten dargestellt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Anlauf M (1994): Hypertonie im Alter. MMV Medizin Verlag, München

    Google Scholar 

  • Anlauf M, Hense HW (2003): Echte und vermeintliche Sparpotenziale in der Hochdrucktherapie – Neues aus dem Zauberhut. Dtsch Med Wschr 128: 1557–1559

    PubMed  Google Scholar 

  • Anlauf M, Weber F (2005): Bedeutung der Therapie mit Antihypertensiva für die kardiovaskuläre Prävention. In: Bundesärztekammer Berlin (Hrgs): Fortschritt und Fortbildung in der Medizin, Band 29, Deutscher Ärzte-Verlag, Köln

    Google Scholar 

  • Anlauf M, Weber F (2012): Neues Verfahren, aber für wen? Deutsches Ärzteblatt 109: 31–3

    Google Scholar 

  • Anlauf M (2013):Individualisierte Entscheidungen bei der Behandlung der Hypertonie. Arzneiverordnung in der Praxis 40: 2–4

    Google Scholar 

  • Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA; ACCF Task Force; ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (2011): Circulation 123: 2434–2506

    Article  PubMed  Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2004): Empfehlungen zur Therapie der arteriellen Hypertonie. 2. Auflage, Arzneiverordnung in der Praxis, Band 31, Sonderheft 2 (Therapieempfehlungen), Internet: www.akdae.de/35/74_Hypertonie_2004_2Auflage.pdf

    Google Scholar 

  • Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL; REACH Registry Investigators (2012): ß-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308: 1340–1349

    Article  PubMed  Google Scholar 

  • Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators (2014): A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370: 1393–1401

    Article  PubMed  Google Scholar 

  • Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group (2008): Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358: 1887–1898

    Google Scholar 

  • Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, McCormack T, Forette F, Gil-Extremera B, Dumitrascu D, Staessen JA, Thijs L, Fletcher A, Bulpitt C; HYVET Study Group (2011): Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 2011 Jan 4; 344: d7541

    Article  Google Scholar 

  • Blood Pressure Lowering Treatment Trialists' Collaboration (2000): Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356: 1955–1964

    Google Scholar 

  • Blood Pressure Lowering Treatment Trialists` Collaboration (2007): Blood Pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J. Hypertension 25: 951–958

    Google Scholar 

  • Boger-Megiddo I, Heckbert SR, Weiss NS, McKnight B, Furberg CD, Wiggins KL, Delaney JA, Siscovick DS, Larson EB, Lemaitre RN, Smith NL, Rice KM, Glazer NL, Psaty BM (2010): Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. BMJ 340:c103

    Article  PubMed Central  PubMed  Google Scholar 

  • Brown MJ (2011): Personalised medicine for hypertension. BMJ 343:d4697

    Article  PubMed  Google Scholar 

  • Campbell CY, Blumenthal RS (2012): Pharmacogenetics of antihypertensive response. Hypertension 59: 1094–1096

    Article  PubMed  Google Scholar 

  • Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee (2003): The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289: 2560–2571

    Google Scholar 

  • Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ; MOXCON Investigators (2003): Adverse mortality effect of central sympathetic inhibition with sustained- release moxonidine in patients with heart failure. Eur J Heart Fail 5: 659–667

    Article  PubMed  Google Scholar 

  • Dahlöf B, Sever PS, Neil R, Poulter NP, Wedel H (2005): Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366: 895–906

    Article  PubMed  Google Scholar 

  • Dasgupta K, Quinn RR, Zarnke KB et al (2014): The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 30: 485–501

    Article  PubMed  Google Scholar 

  • Davis BR, Piller LB, Cutler JA, Curt Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group (2006): Role of diuretics in the prevention of heart failure. The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial. Circulation 113: 2201–2210

    PubMed  Google Scholar 

  • Deutsche Liga zur Bekämpfung des hohen Blutdrucks (2011): Neue Entwicklungen in der Hochdrucktherapie. http://www.hochdruckliga.de/tl_files/content/dhl/downloads/DHL-Leitlinien-2011.pdf (12.06.2012)

  • Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS (2012): Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 59: 1124–1131

    Article  PubMed Central  PubMed  Google Scholar 

  • Elliott WJ, Meyer PM (2007): Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201–207

    PubMed  Google Scholar 

  • Falaschetti E, Mindell J, Knott C, Poulter N (2014): Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet 383: 1912–1919

    Article  PubMed  Google Scholar 

  • Galiè, N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group (2005): Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353: 2148–2157

    Article  PubMed  Google Scholar 

  • Galiè N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G (2008): Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371: 2093–2100

    Article  PubMed  Google Scholar 

  • Giles TD, Weber MA, Basile J, Gradman AH, Bharucha DB, Chen W, Pattathil M; NAC-MD-01 Study Investigators (2014): Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet 383: 1889–1898

    Google Scholar 

  • Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators (2011): Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364: 907–917

    Article  PubMed  Google Scholar 

  • He B, Zhang F, Li X, Tang C, Lin G, Du J, Jin H (2010): Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J 74: 1458–1464

    Article  PubMed  Google Scholar 

  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWIG) (2009): Vergleichende Nutzenbewertung verschiedener antihypertensiver Wirkstoffgruppen als Therapie der ersten Wahl bei Patienten mit essentieller Hypertonie Version 1.0 vom 15.7.2009

    Google Scholar 

  • Jamerson K, Weber MA, Bakris GL, Dahlöf B, Jamerson K, Weber MA, Bakris GL, Dahlöf B (2008): Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 359: 2417–2428

    Article  PubMed  Google Scholar 

  • James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E (2014): 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311: 507–520

    PubMed  Google Scholar 

  • Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR; SHEP Collaborative Research Group (2005): Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95: 29–35

    Article  PubMed  Google Scholar 

  • Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M (2009): Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373: 1275–1281

    PubMed  Google Scholar 

  • Larochelle P, Tobe SW, Lacourciere Y (2014): ß-Blockers in hypertension: studies and metaanalyses over the years. Can J Cardiol 30 (5 Suppl): S16–22

    Google Scholar 

  • Lindholm LH, Carlberg B, Samuelsson O (2005): Should betablockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545–1553

    Article  PubMed  Google Scholar 

  • Liu C, Chen J, Gao Y, Deng B, Liu K (2013): Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev; 2: CD00443–4

    Google Scholar 

  • Montani D, Günther S, Dorfmüller P, Perros F, Girerd B, Garcia G, Jaïs X, Savale L, Artaud-Macari E, Price LC, Humbert M, Simonneau G, Sitbon O (2013): Pulmonary arterial hypertension. Orphanet J Rare Dis 8: 97. [Epub ahead of print]

    Article  PubMed Central  PubMed  Google Scholar 

  • Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A; European Society of Hypertension (2009): Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 27: 2121–2158

    PubMed  Google Scholar 

  • Mancia G, Grassi G (2014): Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement. Hypertension 63: 29–36

    Article  PubMed  Google Scholar 

  • Matsui Y, O’Rourke MF, Hoshide S, Ishikawa J, Shimada K, Kario K (2012): Combined Effect of Angiotensin II Receptor Blocker and Either a Calcium Channel Blocker or Diuretic on Day-by-Day Variability of Home Blood Pressure: The Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study. Hypertension 59: 113–2

    Article  Google Scholar 

  • Meisinger C, Heier M, Völzke H, Löwel H, Mitusch R, Hense HW, Lüdemann J (2006): Regional disparities of hypertension prevalence and management within Germany. J Hypertens 24: 293–299

    PubMed  Google Scholar 

  • Muntner P, Shimbo D, Tonelli M, Reynolds K, Arnett DK, Oparil S (2011): The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension 57: 160–166

    Article  PubMed  Google Scholar 

  • National Clinical Guideline Center (2011): Hypertension. The clinical management of primary hypertension in adults. Clinical Guideline 127

    Google Scholar 

  • National Collaborating Centre for Chronic Conditions (2006): Hypertension (partial update of CG18). London: Royal College of Physicians. Im Internet: http://guidance.nice.org.uk/CG34/guidance/pdf/English

  • National Institute for Health and Care Excellence (2013): QS28 Qualiti standards for hypertension. Internet: http://publications.nice.org.uk/quality-standard-for-hypertension-qs28

  • Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, Redgrave JN, Bull LM, Welch SJ, Cuthbertson FC, Binney LE, Gutnikov SA, Anslow P, Banning AP, Mant D, Mehta Z; Oxford Vascular Study (2005): Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366: 1773–1783

    Google Scholar 

  • Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR (2010a): Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 375: 895–905

    Google Scholar 

  • Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, Poulter NR, Sever PS; ASCOT- BPLA and MRC Trial Investigators (2010b): Effects of beta blockers and calciumchannel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 9: 469–480

    Google Scholar 

  • Roush GC, Holford TR, Guddati AK (2012): Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 59: 1110–1117

    Article  PubMed  Google Scholar 

  • Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ; SUPER-2 Study Group (2011): Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 140: 1274–1283

    Google Scholar 

  • Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R (2006): A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 151: 851.e1–5

    Article  Google Scholar 

  • Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O’Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A (1997): Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350: 757–764

    PubMed  Google Scholar 

  • Staessen JA, Gasowski J, Wang Lj G, Thijs L, Den Hond E, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH (2000): Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355: 865–872

    Article  PubMed  Google Scholar 

  • Staessen JA, Birkenhäger WH (2005): Evidence that new antihypertensives are superior to older drugs. Lancet 366: 869–871

    Article  PubMed  Google Scholar 

  • Strange G, Keogh AM, Williams TJ, Wlodarczyk J, McNeil KD, Gabbay E (2008): Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life. Respirology 13: 674–682

    Article  PubMed  Google Scholar 

  • The ACCORD Study Group (2010): Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med 362: 1575–1585

    PubMed Central  Google Scholar 

  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2000): Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283: 1967–1975

    Article  Google Scholar 

  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002): Major outcomes in hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288: 2981–2997

    Google Scholar 

  • The Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW (2010): A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 363: 620–628

    Google Scholar 

  • The ONTARGET Investigators (2008): Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 358: 1547–1559

    Google Scholar 

  • The Task Force for the Management of Arterial Hypertension of the ESH and the ESC (2007): 2007 Guidelines for the management of arterial hypertension. J Hypertens 25: 1105–1187

    Google Scholar 

  • The Task Force for the management of arterial hypertension of the ESH and the ESC (2013): 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 31: 1281–1357

    Google Scholar 

  • Thijs L, Fagard R, Lijnen P, Staessen JA, Van Hoof R, Amery A (1992): A meta-analysis of outcome trials in elderly hypertensives. J Hypertension 10: 1103–1109

    Article  Google Scholar 

  • Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, Norgiolini S, Bracco C, Porcellati C (2004): Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects. Hypertension 43: 963–969

    Article  PubMed  Google Scholar 

  • Weber F, Anlauf M (2014): Treatment resistant hypertension— investigation and conservative management. Dtsch Arztebl Int 2014; 111: __–__.DOI: 10.3238/arztebl.2014.0

    Google Scholar 

  • Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B (2013): Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 381: 537–545

    PubMed  Google Scholar 

  • Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR (2014): Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med 160: 499–503

    Article  PubMed  Google Scholar 

  • Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, Volmink J. (2007): Betablockers for hypertension (Review). Cochrane Database Syst Rev. 2007 Jan 24;(1): CD00200–3

    Google Scholar 

  • Wiysonge CS, Opie LH (2013): ß-Blockers as initial therapy for hypertension. JAMA 310: 1851–1852

    Article  CAS  PubMed  Google Scholar 

  • Wing LMH, Reid MC, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ; Second Australian National Blood Pressure Study Group (2003): A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583–592

    Article  PubMed  Google Scholar 

  • Zhu QM, Lesnick JD, Jasper JR, MacLennan SJ, Dillon MP, Eglen RM, Blue DR (1999): Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol 126: 1522–1530

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Friedrich-Plettke-Weg 12, 27570, Bremerhaven

    Prof. Dr. med. Manfred Anlauf

  2. St.Walburga Krankenhaus, Schederweg 12, 59870, Meschede

    Prof. Dr. med. Franz Weber

Authors
  1. Prof. Dr. med. Manfred Anlauf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Franz Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Anlauf, M., Weber, F. (2014). Antihypertonika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs- Report 2014. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43487-1_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-43487-1_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43486-4

  • Online ISBN: 978-3-662-43487-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation